Histamine H1 receptor antagonist and anti-allergy agent
Talion® is an anti-allergy agent discovered by Ube Industries and co-developed with Mitsubishi Tanabe Pharma Corporation. It is the first launched drug originally created by pharmaceutical research and development in UBE.
In non-clinical studies, this drug showed type I allergic reaction inhibitory action (PCA and anaphylaxis), histamine antagonistic action, antigen-stimulated eosinophil infiltration inhibitory action, PAF-induced eosinophil infiltration inhibitory action and inhibitory action of interleukin-5 production by peripheral blood mononuclear cells. Moreover, in allergic disease models, superior anti-allergic actions were observed.
Clinical development in Japan commenced in 1991, and the drug was approved for the indication of allergic rhinitis in July 2000 and launched in October. The additional approval for the indications of urticariaand pruritus associated with skin deseases (eczema, dermatitis, prurigo, and pruritus cutaneus ) was approved in January 2002. In July 2007, the Talion® OD tablets, an oral disintegranttablet which is easy to take.
Outside Japan, Talion® has obtained approval in China and Southeast Asia following the South Korean launch of Talion® tablets in July 2004. In the US, the drug has been developed as an ophthalmic solution for allergic conjunctivitis, and it was launched as Bepreve™ in September 2009. Development as a nasal medication is currently underway. In addition, approval was obtained for the ophthalmic solution in South Korea in July 2007.